• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽:一项系统评价与Meta分析方案

Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19: A protocol for a systematic review and meta-analysis.

作者信息

Ren Xiaodan, Shi Yu, Li Guizhong

机构信息

The Second Affiliated Hospital of Army Medical University.

Beibei Traditional Chinese Medical Hospital, Chongqing, China.

出版信息

Medicine (Baltimore). 2020 Nov 25;99(48):e23261. doi: 10.1097/MD.0000000000023261.

DOI:10.1097/MD.0000000000023261
PMID:33235084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7710204/
Abstract

BACKGROUND

Assessing the effectiveness and safety of Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19 is the main purpose of this systematic review protocol.

METHODS

The following electronic databases will be searched from their respective inception dates to October 1, 2020: PubMed, MEDLINE, the Cochrane Library, Embase, WorldSciNet, Ovid, the Allied and Complementary Medicine Database, the Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database (VIP), the Wanfang Database, and the China Biology Medicine Disc. All published randomized controlled trials in English or Chinese related to Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19 will be included. The primary outcome is the time and rate of appearance of coughing. The secondary outcomes are the length of hospital stay. Two reviewers will conduct the study selection, data extraction, and assessment independently. The assessment of risk of bias and data synthesis will be conducted with RevMan V.5.2.

RESULTS

The results will provide a high-quality synthesis of current evidence for researchers in this subject area.

CONCLUSION

The conclusion of our study will provide an evidence to judge whether traditional Chinese medicine formula Xiaoqinglong decoction is an effective intervention for patients with cough caused by COVID-19.

ETHICS AND DISSEMINATION

Formal ethical approval is not necessary as the data cannot be individualized. The results of this protocol will be disseminated in a peer-reviewed journal or presented at relevant conferences.

PROSPERO REGISTRATION NUMBER

CRD42020202079.

摘要

背景

评估中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽的有效性和安全性是本系统评价方案的主要目的。

方法

将从各数据库建库之日起检索至2020年10月1日,检索以下电子数据库:PubMed、MEDLINE、Cochrane图书馆、Embase、WorldSciNet、Ovid、补充与替代医学数据库、科学引文索引、中国生物医学文献数据库、中国知网、维普中文科技期刊数据库、万方数据库和中国生物医学文献光盘数据库。纳入所有已发表的关于中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽的英文或中文随机对照试验。主要结局是咳嗽出现的时间和发生率。次要结局是住院时间。两名评价员将独立进行研究筛选、数据提取和评估。将使用RevMan V.5.2进行偏倚风险评估和数据合成。

结果

结果将为本学科领域的研究人员提供高质量的当前证据综合。

结论

我们研究的结论将为判断中药方剂小青龙汤是否是治疗新型冠状病毒肺炎所致咳嗽患者的有效干预措施提供证据。

伦理与传播

由于数据无法个体化,无需正式伦理批准。本方案的结果将在同行评审期刊上发表或在相关会议上展示。

PROSPERO注册号:CRD42020202

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbb/7710204/91b06ce771dd/medi-99-e23261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbb/7710204/91b06ce771dd/medi-99-e23261-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4bbb/7710204/91b06ce771dd/medi-99-e23261-g001.jpg

相似文献

1
Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19: A protocol for a systematic review and meta-analysis.中药方剂小青龙汤治疗新型冠状病毒肺炎所致咳嗽:一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 Nov 25;99(48):e23261. doi: 10.1097/MD.0000000000023261.
2
Curative effects of traditional Chinese medicine on liver fibrosis: A protocol for a systematic review and meta-analysis.中药抗肝纤维化的疗效:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 Mar 5;100(9):e24587. doi: 10.1097/MD.0000000000024587.
3
Traditional Chinese medicine for symptoms of upper respiratory tract of COVID-19: A protocol for systematic review and meta-analysis.用于新型冠状病毒肺炎上呼吸道症状的中药:一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jul 24;99(30):e21320. doi: 10.1097/MD.0000000000021320.
4
Efficacy of integrative Traditional Chinese and Western medicine for the treatment of patients infected with 2019 novel coronavirus (COVID-19): A protocol for systematic review and meta analysis.中西医结合治疗2019新型冠状病毒感染患者(COVID-19)的疗效:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Jul 17;99(29):e20781. doi: 10.1097/MD.0000000000020781.
5
Efficacy and safety of traditional Chinese herbal formula combined with western medicine for gastroesophageal reflux disease: A protocol for systematic review and meta-analysis.中药复方联合西药治疗胃食管反流病的疗效与安全性:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Oct 9;99(41):e22454. doi: 10.1097/MD.0000000000022454.
6
Efficacy and safety of traditional Chinese herbal formula combined with western medicine for uterine fibroid: A protocol for systematic review and meta-analysis.中药配方联合西药治疗子宫肌瘤的疗效与安全性:系统评价与Meta分析方案
Medicine (Baltimore). 2020 Sep 4;99(36):e22039. doi: 10.1097/MD.0000000000022039.
7
Qingfei Paidu decoction for treating COVID-19: A protocol for a meta-analysis and systematic review of randomized controlled trials.清肺排毒汤治疗新型冠状病毒肺炎:一项随机对照试验的Meta分析和系统评价方案
Medicine (Baltimore). 2020 Sep 4;99(36):e22040. doi: 10.1097/MD.0000000000022040.
8
Chinese medicine for coronavirus disease 2019 as complementary therapy: A protocol for a systematic review and meta-analysis.2019冠状病毒病的中医药辅助治疗:一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 Aug 14;99(33):e21034. doi: 10.1097/MD.0000000000021034.
9
Reduning injection combined with western medicine for pneumonia: A protocol for systematic review and meta-analysis.热毒宁注射液联合西药治疗肺炎:一项系统评价与Meta分析方案
Medicine (Baltimore). 2020 Oct 23;99(43):e22757. doi: 10.1097/MD.0000000000022757.
10
Wendan decoction for primary insomnia: Protocol for a systematic review and meta-analysis.温胆汤治疗原发性失眠:系统评价与Meta分析方案
Medicine (Baltimore). 2017 Nov;96(47):e8906. doi: 10.1097/MD.0000000000008906.

引用本文的文献

1
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.关于具有治疗 SARS-CoV-2(COVID-19)潜力的药物的最新进展。
Drug Resist Updat. 2021 Dec;59:100794. doi: 10.1016/j.drup.2021.100794. Epub 2021 Dec 9.

本文引用的文献

1
What dentists need to know about COVID-19.牙医需要了解的 COVID-19 知识。
Oral Oncol. 2020 Jun;105:104741. doi: 10.1016/j.oraloncology.2020.104741. Epub 2020 Apr 28.
2
[Strategies for vaccine development of COVID-19].[新型冠状病毒肺炎疫苗研发策略]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):593-604. doi: 10.13345/j.cjb.200094.
3
Antiviral treatment of COVID-19.COVID-19 的抗病毒治疗。
Turk J Med Sci. 2020 Apr 21;50(SI-1):611-619. doi: 10.3906/sag-2004-145.
4
Corrigendum to "Traditional Chinese medicine for COVID-19 treatment" [Pharmacol. Res. 155 (2020) 104743].《关于“用于治疗 COVID-19 的中药”的勘误》[《药理学研究》155 (2020) 104743]
Pharmacol Res. 2020 May;155:104768. doi: 10.1016/j.phrs.2020.104768. Epub 2020 Mar 25.
5
Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review.新型冠状病毒病 2019(COVID-19)的胸部 CT 表现:影像学综述。
Eur Radiol. 2020 Aug;30(8):4381-4389. doi: 10.1007/s00330-020-06801-0. Epub 2020 Mar 19.
6
Coronavirus Disease 2019 (COVID-19): A Perspective from China.2019 冠状病毒病(COVID-19):来自中国的视角。
Radiology. 2020 Aug;296(2):E15-E25. doi: 10.1148/radiol.2020200490. Epub 2020 Feb 21.
7
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.系统评价和荟萃分析议定书的首选报告项目(PRISMA-P)2015:详细说明和解释。
BMJ. 2015 Jan 2;350:g7647. doi: 10.1136/bmj.g7647.
8
Effects of Xiaoqinglong decoction on gene expression profiles in a rat chronic obstructive pulmonary disease model.小青龙汤对慢性阻塞性肺疾病大鼠模型基因表达谱的影响。
Biosci Trends. 2012 Oct;6(5):262-9. doi: 10.5582/bst.2012.v6.5.262.
9
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.评估卫生保健干预措施的研究的系统评价和Meta分析报告的PRISMA声明:解释与详述。
PLoS Med. 2009 Jul 21;6(7):e1000100. doi: 10.1371/journal.pmed.1000100.
10
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.GRADE:关于证据质量评级和推荐强度的新共识。
BMJ. 2008 Apr 26;336(7650):924-6. doi: 10.1136/bmj.39489.470347.AD.